CX3CR1 and neoplasm: Concurrent work in murine tumor models by Molgora et al. [191] demonstrated that treatment with anti-TREM2 mAb suppressed tumor growth, augmented antitumor effector T cell responses and reduced MRC1+CX3CR1+ macrophages in the tumor infiltrate when combined with anti-PD-1 mAb therapy [191].